家庭性阿尔茨海默氏病与异合性NPC1突变相关
Diego Lopergolo1,2, Silvia Bianchi1,2, Gian Nicola Gallus1,2
1Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Journal of medical genetics
|November 21, 2023
概括
在一个患有晚期阿尔茨海默病 (AD) 的家庭中发现了一种新的NPC1基因突变. 这一发现表明NPC1突变与AD之间的潜在新遗传联系,为神经退行性疾病机制提供了洞察力.
科学领域:
- 遗传学 是一个遗传学.
- 神经科学是一个神经科学.
- 生物化学 生物化学
背景情况:
- 尼曼-皮克病C型 (NPC) 是一种罕见的,由NPC1突变引起的自体递归神经退行性疾病.
- 异性NPC1突变很少与帕金森症或痴呆症有关.
- 这项研究调查了一家明显具有自体主导晚发性阿尔茨海默病 (AD) 的家庭,该家族携带了一种新型异构性NPC1突变.
研究的目的:
- 为了确定一个大家庭中晚期发病的AD的遗传原因.
- 调查NPC1基因突变在AD病变发生过程中的作用.
- 描述与新型NPC1突变相关的临床和生化特征.
主要方法:
- 对五个兄弟姐妹进行临床评估和神经心理测试.
- 脑脊液 (CSF) 分析粉样沉积,病理和神经退行 (ATN) 生物标志物.
- 结构神经成像,大脑粉样蛋白-位子发射断层扫描 (PET) 和血清氧胆固醇水平评估.
- 下一代测序 (NGS) 面板和整体外基因组测序 (WES) 用于基因分析.
主要成果:
- 在所有受影响的兄弟姐妹中发现了一种新型异构性NPC1突变 (c.3034G>T,p.Gly1012Cys).
- 根据临床和ATN生物标志物 (A +,T +,N +) 概况,四个兄弟姐妹被诊断出患有晚期发作的AD.
- 观察到血清中7-基托胆固醇和胆-3β,5α,6β-三醇的水平升高,表明氧胆固醇代谢发生变化.
结论:
- 在这个家族中,一种新的异构性NPC1突变与自身主导的晚发性遗忘性AD相关,没有典型的NPC特征.
- 观察到的血清氧化的变化支持了这种NPC1突变的致病作用.
- 这项研究强调了NPC1异性和AD之间的潜在新兴关联,为疾病机制提供了洞察力.
更多相关视频
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
8.6K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
相关概念视频
Alzheimer's Disease: Overview
496
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
496
Alzheimer's Disease: Treatment
196
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
196
